Subtype
AIDS-Related Malignant Neoplasm
CI-CAN-00000427Explore in graph →
12 active trials3 approved drugs
- NCIt
- C4046
Loading cancer entity…
Subtype
CI-CAN-00000427Explore in graph →
Clinical trials
66 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01771107 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 41 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02595866 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer |
| completed |
| Phase 1 |
| 58 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Aug 9, 2024 |
| clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT01057121 | Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT01076543 | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2019 | clinicaltrials |
| NCT01016730 | Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 15, 2025source: clinicaltrials